Xvivo Perfusion AB (publ) (XVIPY)
OTCMKTS · Delayed Price · Currency is USD
4.600
-0.150 (-3.16%)
Dec 9, 2025, 4:00 PM EST
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $695.44 million as of January 14, 2026. Its market cap has decreased by -47.92% in one year.
Market Cap
695.44M
Enterprise Value
678.52M
Revenue
86.34M
Ranking
n/a
PE Ratio
219.15
Stock Price
$4.60
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 695.44M, an increase of 1,140.28%. That is a compound annual growth rate of 20.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 13, 2026 | 667.45M | 4.37% |
| Dec 30, 2025 | 639.52M | -54.14% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 811.81M |
| Glass House Brands | 738.79M |
| Elite Pharmaceuticals | 515.71M |
| Northwest Biotherapeutics | 440.23M |
| Nika Pharmaceuticals | 395.06M |
| American Oncology Network | 386.20M |
| CytoDyn | 338.05M |
| Silence Therapeutics | 279.15M |